

CARDIO3 BIOSCIENCES AWARDED PREFERRED ACCESS RIGHTS TO ALL MAYO CLINIC CENTER FOR REGENERATIVE MEDICINE PORTFOLIO

- **Agreement broadens long standing research and development collaboration and ensures Cardio3 BioSciences' preferred access to Mayo Clinic Center for Regenerative Medicine technologies**
- **Agreement objective is to accelerate translation of discovery into clinical practice**

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic. Under this agreement, Mayo grants Cardio3 BioSciences preferred access to technologies developed in the Mayo Clinic Center for Regenerative Medicine, as well as select other Mayo technologies. This agreement is an expansion of a long-standing collaboration, which led to the development of C-Cure®; Cardio3 BioSciences' product candidate now in advanced clinical trial testing (Phase III); an innovative cell therapy based on the discovery of the cardiopoiesis platform by the team of Andre Terzic, M.D., Ph.D. at Mayo Clinic.

Mayo Clinic has identified regenerative medicine as a strategic priority and launched the [Mayo Clinic Center for Regenerative Medicine](#), led by A. Terzic, M.D. The center is designed to discover, translate, and apply regenerative technologies across medical and surgical specialties.

Cardio3 BioSciences identified cellular therapies as the strategic technological pillar of the Company and is looking to further extend its portfolio in this specific area. Building on its core competences and unique expertise in cellular therapies and cardiovascular diseases developed with C-Cure®, now in Phase III trial, Cardio3 BioSciences' access to Mayo Clinic Center for Regenerative Medicine technologies is an extra asset to further strengthen the Company's long term plan to bring the best innovative therapeutic response to unmet medical needs.

With this agreement, Mayo Clinic and Cardio3 BioSciences' unique expertise and competences will come together to accelerate innovative medical advancements to benefit patients. Mayo Clinic will significantly expand its ability to address unmet needs and Cardio3 BioSciences gains access to a broad portfolio in multiple areas such as cardiology, oncology or others, enabling the company to advance regenerative medicine's potential.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: *"We are extremely pleased to significantly extend our collaboration with Mayo Clinic. With the development of the cardiopoiesis platform and the C-Cure clinical program, we have built over the past years solid foundation and mutual trust that will drive our future scientific collaboration. Securing this agreement with the nation's leading clinical institution, offers remarkable opportunities building on the strength of both organizations. Mayo will continue to invent new concepts, while Cardio3 will offer its development expertise to those technologies, as well as guidance in the early development phases to the Mayo research teams. This*

8 OCTOBER 2014

7:00 AM CET

agreement is in line with our business development strategy defined earlier this year, and enables our company to rapidly and significantly enlarge its product portfolio with high quality research programs across multiple therapeutic areas.”

*“We are excited for the opportunity to expand our collaboration with Cardio 3 and accelerate the delivery of novel therapies to patients”, says **Clark Otley, M.D., Medical Director of Mayo Clinic Ventures** which works to commercialize Mayo Clinic technologies for the benefit of patients worldwide.*

Mayo Clinic has a financial interest in Cardio3 Biosciences.

**** END ****

For more information, please contact:

Cardio3 BioSciences

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

www.c3bs.com

Tél. : +32 10 39 41 00

jgrade@c3bs.com

Citigate Dewe Rogerson

Chris Gardner

Tel : +44 (0) 207 638 9571

Chris.Gardner@citigatedr.co.uk

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath^{®ez}, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

About Mayo Clinic

Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.150years.mayoclinic.org ; www.mayoclinic.org ; and www.newsnetwork.mayoclinic.org .

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.